{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:18:34Z","timestamp":1791263914076,"version":"4.1.0"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100008530","name":"FEDER","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001871","name":"FCT","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.ejpb.2015.03.024","type":"journal-article","created":{"date-parts":[[2015,4,6]],"date-time":"2015-04-06T06:27:27Z","timestamp":1428301647000},"page":"149-164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"special_numbering":"C","title":["Development of a novel adjuvanted nasal vaccine: C48\/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity"],"prefix":"10.1016","volume":"93","author":[{"given":"D.","family":"Bento","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.F.","family":"Staats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Borges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2015.03.024_b0005","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11095-009-0011-3","article-title":"Mucosal vaccines: recent progress in understanding the natural barriers","volume":"27","author":"Borges","year":"2010","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2015.03.024_b0010","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/nri2782","article-title":"Mast cell-orchestrated immunity to pathogens","volume":"10","author":"Abraham","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejpb.2015.03.024_b0015","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.it.2007.03.003","article-title":"Mast cells\u2013key effector cells in immune responses","volume":"28","author":"Metz","year":"2007","journal-title":"Trends Immunol."},{"key":"10.1016\/j.ejpb.2015.03.024_b0020","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nri1460","article-title":"Mast-cell responses to pathogens","volume":"4","author":"Marshall","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejpb.2015.03.024_b0025","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/nm1757","article-title":"Mast cell activators: a new class of highly effective vaccine adjuvants","volume":"14","author":"McLachlan","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejpb.2015.03.024_b0030","doi-asserted-by":"crossref","first-page":"e16532","DOI":"10.1371\/journal.pone.0016532","article-title":"Mucosal targeting of a BoNT\/A subunit vaccine adjuvanted with a mast cell activator enhances induction of BoNT\/A neutralizing antibodies in rabbits","volume":"6","author":"Staats","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ejpb.2015.03.024_b0035","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1016\/j.vaccine.2009.03.069","article-title":"The mast cell activator compound 48\/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigen","volume":"27","author":"McGowen","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.ejpb.2015.03.024_b0040","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/jps.22742","article-title":"Stable dry powder formulation for nasal delivery of anthrax vaccine","volume":"101","author":"Wang","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2015.03.024_b0045","doi-asserted-by":"crossref","first-page":"12703","DOI":"10.1128\/JVI.01182-10","article-title":"Interleukin-1 family cytokines as mucosal vaccine adjuvants for induction of protective immunity against influenza virus","volume":"84","author":"Kayamuro","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.ejpb.2015.03.024_b0050","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.4049\/jimmunol.1000589","article-title":"Mast cells contribute to the mucosal adjuvant effect of CTA1-DD after IgG-complex formation","volume":"185","author":"Fang","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejpb.2015.03.024_b0055","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1182\/blood-2006-07-036889","article-title":"Mast cells are crucial for early inflammation, migration of Langerhans cells, and CTL responses following topical application of TLR7 ligand in mice","volume":"110","author":"Heib","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ejpb.2015.03.024_b0060","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.4049\/jimmunol.0900164","article-title":"Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity","volume":"183","author":"McKee","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejpb.2015.03.024_b0065","doi-asserted-by":"crossref","first-page":"e61643","DOI":"10.1371\/journal.pone.0061643","article-title":"Polymyxins as novel and safe mucosal adjuvants to induce humoral immune responses in mice","volume":"8","author":"Yoshino","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ejpb.2015.03.024_b0070","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nri3488","article-title":"Applications of nanotechnology for immunology","volume":"13","author":"Smith","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejpb.2015.03.024_b0075","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.drudis.2011.04.006","article-title":"Particulate vaccines: on the quest for optimal delivery and immune response","volume":"16","author":"De Temmerman","year":"2011","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejpb.2015.03.024_b0350","doi-asserted-by":"crossref","DOI":"10.1007\/s11095-014-1419-y","article-title":"Biomaterials for nanoparticle vaccine delivery systems","author":"Sahdev","year":"2014","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2015.03.024_b0355","article-title":"Nanoparticle vaccines","author":"Zhao","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.ejpb.2015.03.024_b0090","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1440-1711.2004.01288.x","article-title":"Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines","volume":"82","author":"Vajdy","year":"2004","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.ejpb.2015.03.024_b0095","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1586\/erv.09.47","article-title":"Chitosan-based systems for the delivery of vaccine antigens","volume":"8","author":"Arca","year":"2009","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.ejpb.2015.03.024_b0100","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1517\/17425247.2012.697455","article-title":"Chitosan-based delivery systems for mucosal vaccines","volume":"9","author":"Jabbal-Gill","year":"2012","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2015.03.024_b0105","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ejpb.2012.03.021","article-title":"Novel thermal-sensitive hydrogel enhances both humoral and cell-mediated immune responses by intranasal vaccine delivery","volume":"81","author":"Wu","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2015.03.024_b0110","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev-bioeng-071811-150054","article-title":"Mucosal vaccine design and delivery","volume":"14","author":"Woodrow","year":"2012","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"10.1016\/j.ejpb.2015.03.024_b0115","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1586\/erv.11.21","article-title":"Trends in vaccine adjuvants","volume":"10","author":"Schijns","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.ejpb.2015.03.024_b0120","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1586\/erv.10.154","article-title":"Combination adjuvants: the next generation of adjuvants?","volume":"10","author":"Mutwiri","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.ejpb.2015.03.024_b0125","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.intimp.2008.08.013","article-title":"Alginate coated chitosan nanoparticles are an effective subcutaneous adjuvant for hepatitis B surface antigen","volume":"8","author":"Borges","year":"2008","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejpb.2015.03.024_b0130","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejps.2011.05.015","article-title":"Enhancing immunogenicity to PLGA microparticulate systems by incorporation of alginate and RGD-modified alginate","volume":"44","author":"Mata","year":"2011","journal-title":"Eur. J. Pharm. Sci.: Off. J. Eur. Feder. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2015.03.024_b0135","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/jbm.a.32096","article-title":"Effect of alginate on innate immune activation of macrophages","volume":"90","author":"Yang","year":"2009","journal-title":"J. Biomed. Mater. Res. A"},{"key":"10.1016\/j.ejpb.2015.03.024_b0140","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0022-1759(96)00079-8","article-title":"Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood","volume":"196","author":"Bender","year":"1996","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.ejpb.2015.03.024_b0145","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/jps.2600820909","article-title":"Development of a new drug carrier made from alginate","volume":"82","author":"Rajaonarivony","year":"1993","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2015.03.024_b0150","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1208\/s12249-013-9950-4","article-title":"Validation of a new 96-well plate spectrophotometric method for the quantification of compound 48\/80 associated with particles","volume":"14","author":"Bento","year":"2013","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2015.03.024_b0155","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jconrel.2006.06.011","article-title":"Uptake studies in rat Peyer\u2019s patches, cytotoxicity and release studies of alginate coated chitosan nanoparticles for mucosal vaccination","volume":"114","author":"Borges","year":"2006","journal-title":"J. Control. Release: Off. J. Control. Release Soc."},{"key":"10.1016\/j.ejpb.2015.03.024_b0160","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.intimp.2010.02.009","article-title":"Inhibitory effect of phytoglycoprotein (24kDa) on allergy-related factors in compound 48\/80-induced mast cells in vivo and in vitro","volume":"10","author":"Lee","year":"2010","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejpb.2015.03.024_b0165","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1039\/C2MD20073B","article-title":"A mast cell degranulation screening assay for the identification of novel mast cell activating agents","volume":"4","author":"Staats","year":"2013","journal-title":"MedChemComm"},{"key":"10.1016\/j.ejpb.2015.03.024_b0170","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1158\/1535-7163.MCT-10-0207","article-title":"Immune competency of a hairless mouse strain for improved preclinical studies in genetically engineered mice","volume":"9","author":"Schaffer","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejpb.2015.03.024_b0175","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jconrel.2010.01.027","article-title":"Role of trimethylated chitosan (TMC) in nasal residence time, local distribution and toxicity of an intranasal influenza vaccine","volume":"144","author":"Hagenaars","year":"2010","journal-title":"J. Control. Release: Off. J. Control. Release Soc."},{"key":"10.1016\/j.ejpb.2015.03.024_b0180","doi-asserted-by":"crossref","first-page":"5443","DOI":"10.1128\/IAI.00529-07","article-title":"In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity","volume":"75","author":"Staats","year":"2007","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ejpb.2015.03.024_b0185","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ijpharm.2005.03.035","article-title":"Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model","volume":"298","author":"Foged","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.03.024_b0190","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1586\/erv.11.48","article-title":"Current adjuvants and new perspectives in vaccine formulation","volume":"10","author":"Montomoli","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.ejpb.2015.03.024_b0195","series-title":"Vaccine Adjuvants","first-page":"29","article-title":"Harmful and beneficial activities of immunological adjuvants","author":"Stewart-Tull","year":"2000"},{"key":"10.1016\/j.ejpb.2015.03.024_b0200","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1743-8977-6-14","article-title":"Comparative toxicity of 24 manufactured nanoparticles in human alveolar epithelial and macrophage cell lines","volume":"6","author":"Lanone","year":"2009","journal-title":"Part. Fibre Toxicol."},{"key":"10.1016\/j.ejpb.2015.03.024_b0205","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.tiv.2006.10.007","article-title":"In vitro toxicity evaluation of single walled carbon nanotubes on human A549 lung cells","volume":"21","author":"Davoren","year":"2007","journal-title":"Toxicol. In Vitro"},{"key":"10.1016\/j.ejpb.2015.03.024_b0210","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.biologicals.2010.06.002","article-title":"Mode of action of adjuvants: implications for vaccine safety and design","volume":"38","author":"Mastelic","year":"2010","journal-title":"Biologicals: J. Int. Assoc. Biol. Stand."},{"key":"10.1016\/j.ejpb.2015.03.024_b0215","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/nm.2403","article-title":"DNA released from dying host cells mediates aluminum adjuvant activity","volume":"17","author":"Marichal","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejpb.2015.03.024_b0220","doi-asserted-by":"crossref","first-page":"7481","DOI":"10.1074\/jbc.M112.400655","article-title":"Cathepsin-mediated necrosis controls the adaptive immune response by Th2 (T helper type 2)-associated adjuvants","volume":"288","author":"Jacobson","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejpb.2015.03.024_b0225","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1016\/j.biomaterials.2007.08.015","article-title":"Interactions of antigen-loaded polylactide particles with macrophages and their correlation with the immune response","volume":"28","author":"Kanchan","year":"2007","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2015.03.024_b0230","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.addr.2008.09.005","article-title":"Nanoparticles for nasal vaccination","volume":"61","author":"Csaba","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2015.03.024_b0235","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.biomaterials.2013.10.068","article-title":"The localisation of inflammatory cells and expression of associated proteoglycans in response to implanted chitosan","volume":"35","author":"Farrugia","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2015.03.024_b0240","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/S0196-9781(02)00090-6","article-title":"G protein-dependent activation of mast cell by peptides and basic secretagogues","volume":"23","author":"Ferry","year":"2002","journal-title":"Peptides"},{"key":"10.1016\/j.ejpb.2015.03.024_b0245","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0022-3565(25)21370-2","article-title":"Activation of rat peritoneal mast cells by substance P and mastoparan","volume":"250","author":"Mousli","year":"1989","journal-title":"J. Pharmacol. Exp. Therap."},{"key":"10.1016\/j.ejpb.2015.03.024_b0250","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s00011-009-0028-4","article-title":"RBL-2H3 cells are an imprecise model for mast cell mediator release","volume":"58","author":"Passante","year":"2009","journal-title":"Inflamm. Res.: Off. J. Eur. Histamine Res. Soc."},{"key":"10.1016\/j.ejpb.2015.03.024_b0255","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.procbio.2011.10.036","article-title":"Protective effect of chitosan oligosaccharides against Fc\u025bRI-mediated RBL-2H3 mast cell activation","volume":"47","author":"Vo","year":"2012","journal-title":"Process Biochem."},{"key":"10.1016\/j.ejpb.2015.03.024_b0260","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.biomaterials.2011.09.043","article-title":"The suppression of IgE-mediated histamine release from mast cells following exocytic exclusion of biodegradable polymeric nanoparticles","volume":"33","author":"Tahara","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2015.03.024_b0265","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0196-9781(98)00167-3","article-title":"Mast cell degranulating (MCD) peptide: a prototypic peptide in allergy and inflammation","volume":"20","author":"Buku","year":"1999","journal-title":"Peptides"},{"key":"10.1016\/j.ejpb.2015.03.024_b0270","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1021\/mp100210g","article-title":"Antigen-adjuvant nanoconjugates for nasal vaccination: an improvement over the use of nanoparticles?","volume":"7","author":"Slutter","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2015.03.024_b0275","series-title":"Recent Advances in Novel Drug Carrier Systems","article-title":"Novel mucoadhesive polymers for nasal drug delivery","author":"Anand","year":"2012"},{"key":"10.1016\/j.ejpb.2015.03.024_b0280","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.vaccine.2013.01.012","article-title":"A comparison of non-toxin vaccine adjuvants for their ability to enhance the immunogenicity of nasally-administered anthrax recombinant protective antigen","volume":"31","author":"Gwinn","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.ejpb.2015.03.024_b0285","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0378-5173(01)00602-0","article-title":"Clearance characteristics of chitosan based formulations in the sheep nasal cavity","volume":"217","author":"Soane","year":"2001","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.03.024_b0290","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0378-5173(98)00367-6","article-title":"Evaluation of the clearance characteristics of bioadhesive systems in humans","volume":"178","author":"Soane","year":"1999","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.03.024_b0295","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s11095-012-0913-3","article-title":"Efficacy of mucoadhesive hydrogel microparticles of whey protein and alginate for oral insulin delivery","volume":"30","author":"Deat-Laine","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2015.03.024_b0300","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ijbiomac.2013.03.064","article-title":"Oral delivery of insulin from alginate\/chitosan crosslinked by glutaraldehyde","volume":"58","author":"Tahtat","year":"2013","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejpb.2015.03.024_b0305","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.addr.2005.07.001","article-title":"The basics and underlying mechanisms of mucoadhesion","volume":"57","author":"Smart","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2015.03.024_b0310","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.ejpb.2013.06.017","article-title":"Development and characterization of surface modified PLGA nanoparticles for nasal vaccine delivery: effect of mucoadhesive coating on antigen uptake and immune adjuvant activity","volume":"83","author":"Pawar","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2015.03.024_b0315","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nmat2784","article-title":"Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines","volume":"9","author":"Nochi","year":"2010","journal-title":"Nat. Mater."},{"key":"10.1016\/j.ejpb.2015.03.024_b0320","unstructured":"Guideline on Adjuvants in Vaccines for Human Use (EMEA\/CHMP\/VEG\/134716\/2004), in: European Medicines Agency (EMA), London, 2005."},{"key":"10.1016\/j.ejpb.2015.03.024_b0325","doi-asserted-by":"crossref","first-page":"F13","DOI":"10.1097\/QAD.0b013e328360eac6","article-title":"Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission","volume":"27","author":"Watkins","year":"2013","journal-title":"AIDS"},{"key":"10.1016\/j.ejpb.2015.03.024_b0330","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/mi.2012.51","article-title":"IgA is important for clearance and critical for protection from rotavirus infection","volume":"5","author":"Blutt","year":"2012","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.ejpb.2015.03.024_b0335","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1002\/eji.201242372","article-title":"The vaccine adjuvant alum inhibits IL-12 by promoting PI3 kinase signaling while chitosan does not inhibit IL-12 and enhances Th1 and Th17 responses","volume":"42","author":"Mori","year":"2012","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ejpb.2015.03.024_b0340","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/mi.2009.100","article-title":"Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa","volume":"2","author":"Khader","year":"2009","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.ejpb.2015.03.024_b0345","doi-asserted-by":"crossref","first-page":"10638","DOI":"10.1073\/pnas.1002348107","article-title":"Mucosal adjuvant activity of cholera toxin requires Th17 cells and protects against inhalation anthrax","volume":"107","author":"Datta","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641115001575?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641115001575?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T22:52:49Z","timestamp":1747867969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641115001575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":69,"alternative-id":["S0939641115001575"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2015.03.024","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a novel adjuvanted nasal vaccine: C48\/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2015.03.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}